1593-24-4 Usage
Uses
Used in Pharmaceutical Industry:
3-Quinoxalin-2-yl-acrylic acid is used as a pharmaceutical intermediate for the development of new drugs. Its unique chemical structure allows it to interact with biological targets, potentially leading to the discovery of novel therapeutic agents.
Used in Material Sciences:
In the field of material sciences, 3-Quinoxalin-2-yl-acrylic acid is used as a component in the synthesis of advanced materials with specific properties. Its incorporation into these materials can enhance their performance in various applications.
Used in Organic Synthesis:
3-Quinoxalin-2-yl-acrylic acid is used as a building block in organic synthesis for the creation of more complex compounds. Its unique structure and reactivity make it a valuable component in the synthesis of a wide range of organic molecules, including pharmaceuticals, agrochemicals, and other specialty chemicals.
Check Digit Verification of cas no
The CAS Registry Mumber 1593-24-4 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,5,9 and 3 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1593-24:
(6*1)+(5*5)+(4*9)+(3*3)+(2*2)+(1*4)=84
84 % 10 = 4
So 1593-24-4 is a valid CAS Registry Number.
InChI:InChI=1/C11H8N2O2/c14-11(15)6-5-8-7-12-9-3-1-2-4-10(9)13-8/h1-7H,(H,14,15)/b6-5+
1593-24-4Relevant articles and documents
CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS
-
Page 95-96, (2010/02/08)
This invention pertains to certain carbamic acid compounds of the following formula, which inhibit HDAC (histone deacetylase) activity wherein: A is independently an unsubstituted or substituted bicyclic C9-10heteroaryl group (e.g., quinolinyl; quinoxalinyl; benzoxazolyl; benzothiazolyl); Q is an acid leader group, and is independently an unsubstituted or substituted, saturated or unsaturated C1 7alkylene group having a backbone length of 4 or less; with the proviso that if A is unsubstituted benzothiazol-2-yl, then Q is an unsaturated group; and with the proviso that if A is unsubstituted quinolin-6-yl, then Q is unsubstituted at the α-position; and with the proviso that A is not benzimidazol-2-yl; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both invitro and in vivo, to inhibit HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.
